August 22, 2018
CNS Activity of EGFR Tyrosine Kinase Inhibitor in T790M-Positive Advanced NSCLC BookmarkEmma Shtivelman, PhD
Excerpt from The ASCO Post:
“In a planned subgroup analysis of the phase III AURA3 trial reported in the Journal of Clinical Oncology, Wu et al found that the third-generation EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) produced higher central nervous system (CNS) response rates vs platinum plus pemetrexed (Alimta) in patients with advanced EGFR T790M-positive non–small cell lung cancer (NSCLC).
“In AURA3, 419 patients with disease progression on prior EGFR tyrosine kinase inhibitor treatment were randomized 2:1 to receive osimertinib at 80 mg once daily or platinum plus pemetrexed. The current subgroup analysis was conducted in patients with measurable or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiologic review.”
Go to full article published by The ASCO Post on Aug 13, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
September 5, 2017
EGFR-mutant NSCLC: Choice of First-Line Treatment May Get More ComplicatedEmma Shtivelman, PhD
Medical guidelines for treatment of newly diagnosed non-small cell lung cancer (NSCLC) mandate upfront testing of tumor tissue for mutations in the EGFR gene (as well as ALK and ROS gene translocation). EGFR mutations are found in 10 to 15% of white patients, but in patients of East Asian origin such mutations are in encountered in approximately 48%. However, with new data and drugs… Read more »
February 10, 2015
New Drugs Aim to Defeat Tumor Resistance to EGFR InhibitorsEmma Shtivelman, PhD
In recent years, many people with non-small cell lung cancer (NSCLC) have been successfully treated with drugs called EGFR inhibitors. But over time, most patients develop resistance to these drugs, and the drugs stop working. Researchers are hard at work developing new drugs to help patients who can no longer be treated with EGFR inhibitors.